Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Sell
26
ARVN Quote, Financials, Valuation and Earnings
Last price:
$9.05
Seasonality move
:
-4.52%
Day range:
$8.89 - $9.22
52-week range:
$5.94 - $37.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.47x
P/B ratio:
1.11x
Volume:
1.5M
Avg. volume:
2.5M
1-year change:
-71.36%
Market cap:
$622.4M
Revenue:
$263.4M
EPS (TTM):
-$2.77
Analysts' Opinion
-
Consensus RatingArvinas has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $36.22, Arvinas has an estimated upside of 300.25% from its current price of $9.05.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $9.05.
Fair Value
-
According to the consensus of 17 analysts, Arvinas has 300.25% upside to fair value with a price target of $36.22 per share.
ARVN vs. S&P 500
-
Over the past 5 trading days, Arvinas has overperformed the S&P 500 by 0.61% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Arvinas does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arvinas has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Arvinas reported revenues of $59.2M.
Earnings Growth
-
Arvinas has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Arvinas reported earnings per share of -$0.63.
Enterprise value:
-416.4M
EV / Invested capital:
--
Price / LTM sales:
2.47x
EV / EBIT:
--
EV / Revenue:
-1.58x
PEG ratio (5yr expected):
-1.15x
EV / Free cash flow:
1.59x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-16.42%
Net Income Margin (TTM):
-75.51%
Return On Equity:
-32.96%
Return On Invested Capital:
-32.92%
Operating Margin:
-98.31%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $131.3M | $78.5M | $263.4M | -$43.1M | $59.2M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$263.4M | -$401.5M | -$250.3M | -$165.3M | -$58.2M | |
| EBITDA | -$255.2M | -$394.8M | -$243.7M | -$163.6M | -$56.6M | |
| Diluted EPS | -$5.32 | -$6.50 | -$2.77 | -$2.53 | -$0.63 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $703.1M | $1.6B | $1.2B | $1.3B | $1.1B | |
| Total Assets | $717.4M | $1.6B | $1.3B | $1.3B | $1.1B | |
| Current Liabilities | $49.2M | $261.7M | $295.1M | $257.1M | $229.8M | |
| Total Liabilities | $75.2M | $799.9M | $703.9M | $644.6M | $529.7M | |
| Total Equity | $642.2M | $781.7M | $564.9M | $660M | $561.7M | |
| Total Debt | $2M | $1M | $1M | $800K | $600K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$273.5M | -$347.8M | -$259.3M | -$83.1M | -$84.1M | |
| Cash From Investing | $242.8M | $203.5M | $34.7M | -$53.7M | $98.9M | |
| Cash From Financing | $4.7M | $374.7M | $7.9M | $334.8M | $500K | |
| Free Cash Flow | -$280.3M | -$350.7M | -$261.1M | -$83.2M | -$84.4M | |
ARVN
Sector
Market Cap
$622.4M
$35M
Price % of 52-Week High
24.21%
44.47%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
-71.36%
-38.53%
Beta (5-Year)
2.305
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.60
200-day SMA
Sell
Level
$20.76
Bollinger Bands (100)
Sell
Level
9.79 - 21.15
Chaikin Money Flow
Sell
Level
-27.1M
20-day SMA
Buy
Level
$7.57
Relative Strength Index (RSI14)
Buy
Level
52.19
ADX Line
Buy
Level
29.58
Williams %R
Sell
Level
-6.0332
50-day SMA
Sell
Level
$11.24
MACD (12, 26)
Sell
Level
-0.42
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Sell
Level
-8.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.0651)
Sell
CA Score
(Annual)
Level (-1.2755)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.9574)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Stock Forecast FAQ
In the current month, ARVN has received 12 Buy ratings 5 Hold ratings, and 0 Sell ratings. The ARVN average analyst price target in the past 3 months is $36.22.
-
Where Will Arvinas Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arvinas share price will rise to $36.22 per share over the next 12 months.
-
What Do Analysts Say About Arvinas?
Analysts are divided on their view about Arvinas share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arvinas is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Arvinas's Price Target?
The price target for Arvinas over the next 1-year time period is forecast to be $36.22 according to 17 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is ARVN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arvinas is a Buy. 12 of 17 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ARVN?
You can purchase shares of Arvinas via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arvinas shares.
-
What Is The Arvinas Share Price Today?
Arvinas was last trading at $9.05 per share. This represents the most recent stock quote for Arvinas. Yesterday, Arvinas closed at $9.05 per share.
-
How To Buy Arvinas Stock Online?
In order to purchase Arvinas stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Brookfield Stock?
Bill Ackman of Pershing Square Capital has made a number…
Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 26
Saia [SAIA] is down 30.77% over the past day.
Sell
48
APPF alert for Apr 26
AppFolio [APPF] is down 18.16% over the past day.
Sell
15
KNSL alert for Apr 26
Kinsale Capital Group [KNSL] is down 16.33% over the past day.
